Search Bar & Filters
Found 65 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating how well CagriSema and cagrilintide help children and adolescents aged 8 to under 18 years with excess body weight lose weight. This phase 3 study compares these new study drugs with semaglutide, a medication already prescribed for adolescents and adults, and a placebo. The trial aims to understand the efficacy, safety, and pharmacokinetics of these treatments for weight management in young people with overweight or obesity. Participants are randomly assigned to receive once weekly subcutaneous doses of either CagriSema a combination of cagrilintide and semaglutide, cagrilintide alone, semaglutide alone, or placebo in a dose escalation regimen for up to 16 weeks, followed by maintenance for a total of 52 weeks in the main study. Those who participate in the extension study will continue receiving either CagriSema or cagrilintide for up to an additional 156 weeks. Participants receiving semaglutide do not enter the extension phase. The placebo group will receive a matched placebo during the main phase and then continue on the CagriSema regimen during the extension. During the study, participants will be closely monitored through various assessments including body mass index BMI changes, body weight, fat and muscle measurements by imaging methods like MRI and DXA scans, blood tests for metabolic markers, and quality of life questionnaires. These evaluations occur at baseline, week 68, and for some measures, week 224. Safety is monitored by tracking adverse events and other health indicators. The total participation time is about 1.5 years in the main study and up to nearly 5 years if including the extension phase.
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Ifinatamab Deruxtecan I-DXd compared to the treatment chosen by a physician for people with relapsed small cell lung cancer SCLC. This Phase 3 study aims to see if I-DXd can help participants live longer than current treatments, while also examining other effects such as patient-reported outcomes, immune response, and the drugs behavior in the body. Participants will be randomly assigned to one of two groups. One group will receive I-DXd as an intravenous infusion at a dose of 12 mgkg every 21 days until the disease worsens, unacceptable side effects occur, or other stopping reasons arise. The other group will receive one of the standard treatments chosen by their doctortopotecan, lurbinectedin, or amrubicinaccording to local approved dosing guidelines and until treatment discontinuation criteria are met. During the study, participants will be closely monitored with regular imaging and assessments to track tumor response, disease progression, and quality of life using questionnaires. Safety events and immune responses will also be recorded. Pharmacokinetic samples will be collected at specified times to understand how I-DXd behaves in the body. Participants may remain in the study for up to approximately 3.7 years, allowing for long-term evaluation of outcomes and safety.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are investigating whether adding intismeran autogene to pembrolizumab after surgery helps prevent cancer from returning in people with non-small cell lung cancer NSCLC whose tumors did not fully respond to treatment before surgery. This randomized phase 3 clinical trial compares pembrolizumab combined with intismeran autogene versus pembrolizumab with placebo in participants with resectable Stage II to IIIB NSCLC. The study focuses on individuals who have not achieved a complete pathological response after neoadjuvant therapy, aiming to improve disease-free survival. Participants receive neoadjuvant treatment consisting of pembrolizumab via intravenous infusion every 3 weeks for up to 4 cycles, combined with background chemotherapy chosen by the investigator. After surgery, the adjuvant treatment phase involves pembrolizumab given intravenously every 6 weeks for up to 7 cycles, plus either intismeran autogene or placebo administered by intramuscular injection every 3 weeks for up to 9 doses. The neoadjuvant phase lasts about 12 weeks, and the adjuvant phase extends up to approximately 42 weeks. During the study, participants will have regular assessments including monitoring for disease recurrence, survival, and quality of life using standardized questionnaires. Researchers will track adverse events and treatment tolerability throughout the trial, with follow-up lasting up to over 8 years to evaluate long-term outcomes. The main measurement is disease-free survival, with additional evaluations of overall survival, distant metastasis-free survival, and lung cancer-specific survival, along with patient-reported quality of life and safety data.
Actively Recruiting
Non-small cell lung cancer NSCLC is a disease where cancer cells grow uncontrollably in lung tissues. This trial evaluates whether the investigational drug telisotuzumab vedotin works better than docetaxel and assesses its safety in adults with previously treated NSCLC that overexpresses c-Met. The study is a Phase 3 randomized trial involving about 768 participants worldwide to compare disease activity and side effects of these treatments. Participants will be randomly assigned to receive either telisotuzumab vedotin every two weeks or docetaxel every three weeks, both given as intravenous infusions. Treatment continues until specific discontinuation criteria are met. Those who benefit may have the option to continue treatment through an extension or rollover study. The study aims to compare how these two treatments affect disease progression and survival. During the study, participants will have regular hospital or clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers will measure progression-free survival and overall survival up to about 39 months, along with response rates and quality of life indicators. The study includes detailed safety monitoring and may involve a higher treatment burden than standard care.
1-10 of 65
1